Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
meeting save search
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
Published: 2024-04-09 (Crawled : 12:30) - prnewswire.com
GNPX | $2.16 -2.26% -2.31% 17K
|
Health Technology
|
| O: 2.36%
H: 6.6%
C: 1.32%
reqorsa lung report positive treatment system preclinical for meeting therapy
Stellantis Annual General Meeting Live Webcast Available
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
STLA | News | $25.75 -0.16% 0.35% 6.3M
|
Manufacturing
|
| O: 1.74%
H: 0.0%
C: 0.0%
meeting
Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
QLGN | $0.291 -2.15% -2.2% 27K
|
Health Technology
|
| O: 3.2%
H: 0.0%
C: -0.28%
qn-302 association positive cancer research meeting therapeutics
ContextLogic Encourages Stockholders to Vote at the Upcoming Special Meeting
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
WISH | $5.75 15.93% 13.74% 3.7M
|
|
| O: -0.7%
H: 0.88%
C: -1.58%
meeting
Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
GALT | $3.36 -0.59% -0.6% 150K
|
Health Technology
|
| O: 2.19%
H: 6.15%
C: 5.35%
metabolic positive for meeting hypertension therapeutics study
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
TPST | $3.18 -2.75% -2.83% 320K
|
Manufacturing
|
| O: 2.83%
H: 4.5%
C: -3.25%
tpst-1120 preclinical for meeting
GenFleet Therapeutics Announces Potent Anti-tumor Efficacy of GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, and its Potential in Combination Therapy with RAF/MEK Clamp at 2024 AACR Annual Meeting
Published: 2024-04-09 (Crawled : 11:00) - prnewswire.com
VSTM | $10.19 -6.0% -6.38% 67K
|
Health Technology
|
| O: 5.64%
H: 1.41%
C: -2.89%
gfh375 meeting therapeutics potential therapy
Bilibili Inc. to Hold Annual General Meeting on June 28, 2024
Published: 2024-04-09 (Crawled : 09:00) - globenewswire.com
BILI | $11.07 0.36% 0.36% 3.9M
|
Technology Services
|
| O: 4.48%
H: 4.64%
C: 4.47%
meeting
Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024
Published: 2024-04-09 (Crawled : 01:00) - elevationoncology.com
ELEV | $4.03 -2.66% -2.73% 320K
|
Professional, Scientific, and T...
|
| O: -0.85%
H: 1.5%
C: 0.64%
preclinical for meeting program
Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024
Published: 2024-04-08 (Crawled : 00:00) - biospace.com/
EXAS | $63.45 0.36% 0.36% 1.6M
|
Health Technology
|
| O: 0.21%
H: 0.0%
C: 0.0%
test sciences meeting study
Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024
Published: 2024-04-08 (Crawled : 23:00) - biospace.com/
ELEV | $4.03 -2.66% -2.73% 320K
|
Professional, Scientific, and T...
|
| O: -3.87%
H: 0.0%
C: 0.0%
preclinical for meeting program
Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024
Published: 2024-04-08 (Crawled : 23:00) - biospace.com/
NUVL | $62.97 -1.99% -2.03% 610K
|
|
| O: 0.01%
H: 0.0%
C: -2.52%
nvl-330 preclinical meeting
Diego Rodriguez Nominated to Stand for Election to TrueCar's Board of Directors at May 23, 2024 Annual Meeting
Published: 2024-04-08 (Crawled : 22:00) - prnewswire.com
TRUE F | $2.82 -1.74% -1.77% 190K
|
Technology Services
|
| O: 0.61%
H: 0.46%
C: -0.61%
for meeting
Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024
Published: 2024-04-08 (Crawled : 21:00) - globenewswire.com
VINC | $0.8967 -5.63% -5.97% 530K
|
|
| O: -65.69%
H: 0.84%
C: -35.37%
vip236 pharma association positive cancer pipeline research for meeting
iCAD’s ProFound AI Suite Uncovers Hidden Heart Disease Risk According to New Data Presented at American College of Cardiology Meeting
Published: 2024-04-08 (Crawled : 21:00) - globenewswire.com
ICAD | $1.57 0.64% 0.64% 140K
|
Technology Services
|
| O: 5.7%
H: 11.98%
C: 7.78%
disease risk meeting heart cardiology
Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting
Published: 2024-04-08 (Crawled : 21:00) - globenewswire.com
CLLS | $2.48 0.81% 0.4% 15K
|
Health Technology
|
| O: 4.83%
H: 0.0%
C: -2.48%
talen for meeting
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
Published: 2024-04-08 (Crawled : 20:00) - globenewswire.com
CRDF | $4.355 -3.22% -3.33% 830K
|
Health Services
|
| O: 0.85%
H: 5.73%
C: -4.55%
ongoing preclinical meeting study
Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Published: 2024-04-08 (Crawled : 20:00) - globenewswire.com
IPSC | $2.97 4.58% 4.38% 150K
|
Professional, Scientific, and T...
|
| O: -1.59%
H: 8.87%
C: 7.8%
association cancer cell research preclinical for meeting technology therapeutics therapy platform
Texas Instruments to webcast its 2024 annual meeting of stockholders
Published: 2024-04-08 (Crawled : 18:00) - prnewswire.com
TXN | $163.61 -1.26% -1.28% 5.5M
|
Electronic Technology
|
| O: 0.07%
H: 1.58%
C: 1.1%
meeting
Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024
Published: 2024-04-08 (Crawled : 17:00) - globenewswire.com
MRUS | $40.41 -1.56% -1.58% 240K
|
Health Technology
|
| O: 0.0%
H: 0.49%
C: -1.54%
cancer preclinical meeting
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.